sequence stringlengths 4 17.9k | seq_id stringlengths 1 6 | pn stringclasses 996
values | title stringclasses 871
values | pbdt int64 20.2M 20.3M | status int64 1 225 ⌀ | family_country listlengths 1 55 | modified_info stringlengths 112 8.31k ⌀ |
|---|---|---|---|---|---|---|---|
tgatggtgaaatgtccaaatt | 471 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgatggtgaaatgtccaaatt | 471 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgatggtgaaatgtccaaatt | 831 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgatggtgaaatgtccaaatt | 831 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgatggtgaaatgtccaaatt | 831 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tttgcaaagcgagagattctttc | 1790 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tttgcaaagcgagagattctttc | 1790 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tttgcaaagcgagagattctttc | 1790 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
atagagtcatacattaatgaatg | 180 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
atagagtcatacattaatgaatg | 180 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
atagagtcatacattaatgaatg | 180 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
atagagtcatacattaatgaatg | 360 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
atagagtcatacattaatgaatg | 360 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
atagagtcatacattaatgaatg | 360 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gggtcacatcttaagtaaaatga | 415 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gggtcacatcttaagtaaaatga | 415 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gggtcacatcttaagtaaaatga | 415 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
attctggtcatggatctctttat | 1017 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
attctggtcatggatctctttat | 1017 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
attctggtcatggatctctttat | 1017 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
attctggtcatggatctctttat | 657 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
attctggtcatggatctctttat | 657 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
attctggtcatggatctctttat | 657 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgaaggaaatatactaaactt | 538 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgaaggaaatatactaaactt | 538 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgaaggaaatatactaaactt | 538 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgaaggaaatatactaaactt | 900 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgaaggaaatatactaaactt | 900 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgaaggaaatatactaaactt | 900 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
agattctttccctgacggtaaag | 1771 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
agattctttccctgacggtaaag | 1771 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
agattctttccctgacggtaaag | 1771 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaagtactgaatgtgcatggaat | 660 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaagtactgaatgtgcatggaat | 660 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaagtactgaatgtgcatggaat | 660 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaagtactgaatgtgcatggaat | 1021 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaagtactgaatgtgcatggaat | 1021 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaagtactgaatgtgcatggaat | 1021 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
ttgatttcctaaaatcagaattt | 398 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
ttgatttcctaaaatcagaattt | 398 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
ttgatttcctaaaatcagaattt | 398 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaaatttcatcaagtgctgaaga | 1139 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaaatttcatcaagtgctgaaga | 1139 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaaatttcatcaagtgctgaaga | 1139 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaaatttcatcaagtgctgaaga | 775 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaaatttcatcaagtgctgaaga | 775 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaaatttcatcaagtgctgaaga | 775 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
actgtcatttgtttcaaagtt | 1453 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
actgtcatttgtttcaaagtt | 1453 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
actgtcatttgtttcaaagtt | 1453 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
actgtcatttgtttcaaagtt | 1367 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
actgtcatttgtttcaaagtt | 1367 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
actgtcatttgtttcaaagtt | 1367 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
agttcgaatggttcgtttgagct | 108 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
agttcgaatggttcgtttgagct | 108 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
agttcgaatggttcgtttgagct | 108 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
agttcgaatggttcgtttgagct | 288 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
agttcgaatggttcgtttgagct | 288 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
agttcgaatggttcgtttgagct | 288 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
cuguagguugcuuaaaaggga | 71 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
cuguagguugcuuaaaaggga | 70 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
cuguagguugcuuaaaaggga | 380 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
cuguagguugcuuaaaaggga | 381 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gcuggauaagaagcugcuguu | 281 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gcuggauaagaagcugcuguu | 488 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uuuaagcaaccuacaggggcagc | 530 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uuuaagcaaccuacaggggcagc | 169 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uuuaagcaaccuacaggggcagc | 531 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uuuaagcaaccuacaggggcagc | 168 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gaccucaauaccccaagucca | 370 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gaccucaauaccccaagucca | 60 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gaccucaauaccccaagucca | 59 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gaccucaauaccccaagucca | 369 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uucagggaacugaagccaucggu | 140 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uucagggaacugaagccaucggu | 502 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uucagggaacugaagccaucggu | 501 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uucagggaacugaagccaucggu | 139 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
cuuuauuagggacagcauguuua | 310 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
cuuuauuagggacagcauguuua | 620 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
aaguauguucucaugucuuca | 468 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
aaguauguucucaugucuuca | 261 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
guugcuuuaaggggaaaguau | 279 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
guugcuuuaaggggaaaguau | 486 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gccccugaagguugcuuuaag | 285 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gccccugaagguugcuuuaag | 492 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
cuacauggaacaagccuccaa | 241 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
cuacauggaacaagccuccaa | 447 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
cuacauggaacaagccuccaa | 240 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
cuacauggaacaagccuccaa | 448 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gcugccccuguagguugcuua | 64 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gcugccccuguagguugcuua | 374 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gcugccccuguagguugcuua | 373 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gcugccccuguagguugcuua | 63 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
auugaggucucaggcagccacgg | 154 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
auugaggucucaggcagccacgg | 515 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
auugaggucucaggcagccacgg | 516 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
auugaggucucaggcagccacgg | 153 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
acuggagcaccguuaaggaca | 42 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
acuggagcaccguuaaggaca | 43 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
acuggagcaccguuaaggaca | 353 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.